The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of...

Full description

Bibliographic Details
Main Authors: Miller Andrew F, Beck Adam W, Sullivan Laura A, Dineen Sean P, Carbon Juliet G, Mamluk Roni, Wong Henry, Brekken Rolf A
Format: Article
Language:English
Published: BMC 2008-11-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/8/352

Similar Items

Similar Items